CTI BioPharma Corp (NASDAQ:CTIC) announced the appointment of Bruce J. Seeley as Executive Vice President and Chief Commercial Officer, reporting to James Bianco, …
Roth Capital analyst Debjit Chattopadhyay weighed in with a few of his opinions on CTI BioPharma Corp (NASDAQ:CTIC) after the company released new patient-reported outcome (PRO) …
CTI BioPharma Corp (NASDAQ:CTIC) announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute myeloid leukemia (AML) …
CTI BioPharma Corp (NASDAQ:CTIC) and Baxter International’s BioScience business announced new patient-reported outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor …
CTI BioPharma Corp (NASDAQ:CTIC) shares increased 9.6% to $2.
CTI BioPharma Corp (NASDAQ:CTIC) and Baxter International’s BioScience business announced that Patient Reported Outcomes (PROs) data from the Phase 3 PERSIST-1 trial, evaluating …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on CTI BioPharma Corp. (NASDAQ:CTIC), reiterating a Buy rating and price target of $4.
The ASCO 2015 meeting is proving to be a big hit in the world of biotech; and CTIC is making waves. CTI BioPharma …
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares rose more than +10% in pre-market trading to $32.
CTI BioPharma Corp (NASDAQ:CTIC) and Baxter International Inc. (NYSE:BAX) announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for …
